Loading...
•
Sep 30, 2021
Rxsight Q3 2021 Earnings Report
Reported financial results for the three months ended September 30, 2021.
Key Takeaways
RxSight reported Q3 2021 revenue of $5.8 million, a 39% increase compared to Q3 2020. The revenue growth was primarily due to a 55% increase in LDDs sold and a 31% increase in LALs sold. Net loss for the quarter was $(12.7) million, or $(0.68) per share.
Achieved third quarter 2021 revenue of $5.8 million, representing growth of 39% compared to the prior year period and 18% growth over the second quarter of 2021.
Sold 31 Light Delivery Devices (LDD™s), expanding the installed base to 161 LDDs as of September 30, 2021.
Sold 1,977 Light Adjustable Lenses (LAL®s).
Completed roll-out of the ActivShield™ LAL, with a UV protection layer built into the lens.
Forward Guidance
RxSight projects 2021 full year revenue to be between $21.0 million and $21.4 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...